Alzheimer’s disease (AD) is known to begin many years before clinical symptoms become obvious, with subtle brain changes occurring long before noticeable memory loss or cognitive decline. Among the earliest brain regions affected are the hippocampus and entorhinal cortex, which are essential for spatial navigation. This has encouraged researchers to investigate whether impairments in navigation ability may serve as early indicators of AD risk. One important navigation process is path integration (PI), the brain’s ability to estimate position and direction using internal cues such as movement and balance. Because these systems may deteriorate early in AD, PI impairment has emerged as a promising behavioural marker of preclinical neurodegeneration.
To explore this possibility, researchers led by Senior Assistant Professor Kazuya Kawabata, Dr. Sayuri Shima, and Prof. Hirohisa Watanabe from the Department of Neurology at Fujita Health University, Japan, examined whether subtle impairments in virtual-reality path integration (VR-PI) could predict future brain degeneration in cognitively healthy adults. Their findings were published in Alzheimer’s Research & Therapy on April 20, 2026. The study aimed to determine whether navigation-based performance could reflect early structural and biological changes associated with neurodegenerative disease before clinical symptoms emerge.
The study followed 71 cognitively unimpaired adults over approximately one year. At baseline, participants completed an immersive VR navigation task designed to measure PI ability. In the virtual environment, participants travelled to two checkpoints and were then required to return to their starting position without visual guidance. Researchers measured PI error, defined as the distance from the correct starting point, and angular error, which reflected directional deviation. Participants also underwent high-resolution magnetic resonance imaging (MRI) scans to assess changes in cortical thickness and brain volume over time. In addition, blood biomarkers associated with AD, including p-tau181 and glial fibrillary acidic protein (GFAP), were evaluated.
The findings revealed that individuals with higher PI error at baseline experienced greater cortical thinning and brain volume loss during follow-up. These structural changes were observed in regions known to be vulnerable during the early stages of AD, including the parahippocampal gyrus, middle temporal gyrus, posterior cingulate cortex, and caudal middle frontal gyrus. Angular error showed similar associations, although age-related effects were somewhat weaker, supporting the reliability of navigation-based measures as indicators of early neurodegeneration.
Importantly, poorer VR-PI performance was also linked to biological markers of AD. Higher PI and angular errors were associated with increased plasma p-tau181 levels, while PI error was additionally linked to GFAP levels. These results suggest that navigation deficits reflect underlying molecular and structural changes rather than simple performance variation. Notably, PI error was able to identify individuals showing the most rapid decline in the parahippocampal region with high accuracy, highlighting its potential value as an early screening measure.
According to Dr. Kawabata, the findings suggest that VR-PI performance captures both blood biomarker and MRI signatures that emerge before overt clinical impairment. Overall, the study demonstrates that impaired path integration is closely associated with subsequent brain degeneration and AD-related biological changes, even among cognitively healthy individuals. By linking behavioural performance with structural and molecular indicators, the research highlights VR-PI as a promising tool for early detection and monitoring of neurodegenerative diseases. The researchers believe this approach may eventually support earlier therapeutic intervention, potentially delaying disease progression while preserving cognitive function and quality of life.
More information: Kazuya Kawabata et al, VR-based path integration predicts individual risk of rapid cortical decline: a one-year longitudinal study in cognitively unimpaired adults, Alzheimer’s Research & Therapy. DOI: 10.1186/s13195-026-02056-x
Journal information: Alzheimer’s Research & Therapy Provided by Fujita Health University
